Quince Therapeutics (NASDAQ:QNCX) Rating Increased to Strong-Buy at RODMAN&RENSHAW

RODMAN&RENSHAW upgraded shares of Quince Therapeutics (NASDAQ:QNCX) to a strong-buy rating in a research report report published on Tuesday, Zacks.com reports.

A number of other research firms have also weighed in on QNCX. EF Hutton Acquisition Co. I raised shares of Quince Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 22nd. Rodman & Renshaw initiated coverage on shares of Quince Therapeutics in a report on Tuesday. They issued a “buy” rating and a $11.00 target price for the company.

Quince Therapeutics Stock Down 4.9 %

Shares of NASDAQ QNCX opened at $1.54 on Tuesday. The firm has a market cap of $66.65 million, a PE ratio of -1.22 and a beta of 0.86. Quince Therapeutics has a 12-month low of $0.51 and a 12-month high of $1.79. The company’s fifty day simple moving average is $0.82 and its 200 day simple moving average is $0.81. The company has a quick ratio of 6.15, a current ratio of 6.15 and a debt-to-equity ratio of 0.29.

Quince Therapeutics (NASDAQ:QNCX) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.18) earnings per share for the quarter.

Insider Buying and Selling

In related news, CEO Dirk Thye acquired 77,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 29th. The stock was acquired at an average price of $0.69 per share, for a total transaction of $53,475.00. Following the completion of the acquisition, the chief executive officer now owns 766,941 shares of the company’s stock, valued at approximately $529,189.29. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Dirk Thye acquired 77,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 29th. The stock was acquired at an average price of $0.69 per share, for a total transaction of $53,475.00. Following the completion of the acquisition, the chief executive officer now owns 766,941 shares of the company’s stock, valued at approximately $529,189.29. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, President Charles S. Ryan acquired 48,387 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The shares were bought at an average price of $0.65 per share, with a total value of $31,451.55. Following the acquisition, the president now directly owns 122,461 shares of the company’s stock, valued at $79,599.65. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 158,887 shares of company stock worth $105,609. Insiders own 16.80% of the company’s stock.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.